Premium
Olaparib
Author(s) -
Goulooze S. C.,
Cohen A. F.,
Rissmann R.
Publication year - 2016
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/bcp.12761
Subject(s) - olaparib , poly adp ribose polymerase , homologous recombination , ovarian cancer , synthetic lethality , dna repair , cancer research , polymerase , breast cancer , medicine , parp inhibitor , dna damage , microbiology and biotechnology , cancer , dna , biology , genetics , chemistry
Olaparib is used to treat BReast CAncer susceptibility protein (BRCA)‐associated, platinum‐sensitive ovarian cancer. Olaparib inhibits poly(ADP‐ribose) polymerase, thereby blocking the repair of single‐strand DNA breaks. This results in synthetic lethality in BRCA‐associated cancer cells, which have a dysfunction of another DNA repair pathway – homologous recombination.